We evaluated the impact of bufotenine derivatives on 6 serotonin receptor subtypes associated with depression (5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2C, and 5-HT7) using the GloSensor cAMP assay to measure Gi and Gs activation and the IP-One assay to assess Gq activation, thereby detecting signaling activity at each receptor. Here, GNAI1 is linked to depressive disorder.